* AVITA Medical Inc RCEL.OQ RCEL.O is expected to show a
rise
in quarterly revenue when it reports results on February 23.
* The Valencia California California-based company is
expected to
report a 25.1% increase in revenue to $8.675 million from $6.94
million a year ago, according to the mean estimate from 4
analysts, based on Refinitiv data.
* Refinitiv's mean analyst estimate for AVITA Medical Inc
is for
a loss of 29 cents per share.
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 5 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in
the last
three months.
* Wall Street's median 12-month price target for AVITA
Medical Inc
is $16, above its last closing price of $9.12.
Previous quarterly performance (using preferred earnings measure
in US dollars).
QUARTER STARMINESM REFINITIV ACTUAL BEAT, SURPRI
ENDING ARTESTIMAT IBES MET, SE %
E® ESTIMATE MISSED
Sep. 30 2022 -0.34 -0.34 -0.22 Beat 35.2
Jun. 30 2022 -0.38 -0.39 -0.25 Beat 35.9
Mar. 31 2022 -0.39 -0.38 -0.38 Met 0
-0.34
This summary was machine generated February 21 at 22:59 GMT.
All figures in US dollars unless otherwise stated